Abstract
Advances in bioinformatics using next-generation sequencing have dramatically identified new molecules involved in the pathogenesis of various diseases. As a result, many molecularly targeted therapeutics have been developed in medicine including veterinary medicine. In the field of veterinary medicine, toceranib, a multikinase inhibitor was approved 2009 following masitinib, which was the first molecularly target drug approved in 2008. Toceranib is originally approved as a treatment for mast cell tumors, but has been shown to be effective in other tumors as well. Therefore, there is a lot of potential for approved anti-cancer drugs to be used to treat other another type of diseases such as neurodegenerative diseases. Immunotherapies and cancer vaccine are also emerging as targeted therapeutics. In this review, we will discuss the approved molecularly targeted drugs and high potential drugs currently in clinical trials.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
